Burns
Volume 36, Issue 3 , Pages 335-342 , May 2010

Macrophage migration inhibitory factor—A potential diagnostic tool in severe burn injuries?

  • Gerrit Grieb

      Affiliations

    • Department of Plastic Surgery, Hand and Burn Surgery, Medical Faculty, RWTH Aachen University, Germany
    • These authors contributed equally to this study.
  • ,
  • David Simons

      Affiliations

    • Department of Plastic Surgery, Hand and Burn Surgery, Medical Faculty, RWTH Aachen University, Germany
    • Department of Biochemistry and Molecular Cell Biology, Medical Faculty, RWTH Aachen University, Germany
    • These authors contributed equally to this study.
  • ,
  • Andrzej Piatkowski

      Affiliations

    • Department of Plastic Surgery, Hand and Burn Surgery, Medical Faculty, RWTH Aachen University, Germany
  • ,
  • Jürgen Bernhagen

      Affiliations

    • Department of Biochemistry and Molecular Cell Biology, Medical Faculty, RWTH Aachen University, Germany
  • ,
  • Guy Steffens

      Affiliations

    • Department of Biochemistry and Molecular Cell Biology, Medical Faculty, RWTH Aachen University, Germany
    • Corresponding Author InformationCorresponding author at: Department of Biochemistry and Molecular Cell Biology, University Hospital, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. Tel.: +49 241 8088843; fax: +49 241 8082427.
  • ,
  • Norbert Pallua

      Affiliations

    • Department of Plastic Surgery, Hand and Burn Surgery, Medical Faculty, RWTH Aachen University, Germany

,Accepted 17 April 2009.

References 

  1. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800
  2. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587–596
  3. Schober A, Bernhagen J, Weber C. Chemokine-like functions of MIF in atherosclerosis. J Mol Med. 2008;86:761–770
  4. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 2008;117:1594–1602
  5. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microb Infect. 2002;4:449–460
  6. Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov. 2006;5:399–410
  7. Froidevaux C, Roger T, Martin C, Glauser MP, Calandra T. Macrophage migration inhibitory factor (MIF) and innate immune responses to bacterial infections. Crit Care Med. 2001;29:S13–S15
  8. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999;189:341–346
  9. Calandra T, Echtenacher B, Le Roy D, Pugin J, Metz CN, Hültner L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor (MIF). Nat Med. 2000;6:164–169
  10. Calandra T, Spiegel LA, Metz CN, Bucala R. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA. 1998;95:11383–11388
  11. Tohyama S, Onodera S, Tohyama H, Yasuda K, Nishihira J, Mizue Y, et al. A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis. Gene Ther. 2008;15:1513–1522
  12. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993;365:756–759
  13. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377:68–71
  14. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry. 1994;33:14144–14155
  15. Roger T, David J, Glauser M, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor-4. Nature. 2001;414:920–924
  16. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med. 1997;3:320–323
  17. Beishuizen A, Thijs LG, Haanen C, Vermes I. Macrophage migration inhibitory factor and hypothalamo–pituitary–adrenal function during critical illness. J Clin Endocrinol Metab. 2001;86:2811–2816
  18. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med. 2001;27:1412–1415
  19. Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis. 2007;44:1321–1328
  20. Sprong T, Pickkers P, Geurts-Moespot A, van der Ven-Jongekrijg J, Neeleman C, Knaup M, et al. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock. 2007;27:482–487
  21. Jeschke MG, Einspanier R, Klein D, Jauch KW. Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med. 2002;8:443–450
  22. Garner LB, Willis MS, Carlson DL, DiMaio JM, White MD, White DJ, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol. 2003;285:H2500–H2509
  23. Willis MS, Carlson DL, Dimaio JM, White MD, White DJ, Adams GA, et al. Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury. Am J Physiol Heart Circ Physiol. 2005;288:H795–804
  24. Pallua N, Low JF, von Heimburg D. Pathogenic role of interleukin-6 in the development of sepsis. Part II. Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model. Crit Care Med. 2003;31:1495–1501
  25. Pallua N, von Heimburg D. Pathogenic role of interleukin-6 in the development of sepsis. Part I. Study in a standardized contact burn murine model. Crit Care Med. 2003;31:1490–1494
  26. Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med. 1999;27:498–504
  27. Carsin H, Assicot M, Feger F, Roy O, Pennacino I, Le Bever H, et al. Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury. Burns. 1997;23:218–224
  28. Sachse C, Machens HG, Felmerer G, Berger A, Henkel E. Procalcitonin as a marker for the early diagnosis of severe infection after thermal injury. J Burn Care Rehabil. 1999;20:354–360
  29. von Heimburg D, Stieghorst W, Khorram-Sefat R, Pallua N. Procalcitonin—a sepsis parameter in severe burn injuries. Burns. 1998;24:745–750
  30. Lavrentieva A, Kontakiotis T, Lazaridis L, Tsotsolis N, Koumis J, Kyriazis G, et al. Inflammatory markers in patients with severe burn injury. What is the best indicator of sepsis?. Burns. 2007;33:189–194
  31. Bargues L, Chancerelle Y, Catineau J, Jault P, Carsin H. Evaluation of serum procalcitonin concentration in the ICU following severe burn. Burns. 2007;33:860–864
  32. Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. Ann Emerg Med. 1982;11:260–262
  33. Vincent JL. Organ dysfunction in patients with severe sepsis. Surg Infect (Larchmt). 2006;7(Suppl. 2):S69–72
  34. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett. 2003;551:78–86

PII: S0305-4179(09)00139-9

doi: 10.1016/j.burns.2009.04.019

Burns
Volume 36, Issue 3 , Pages 335-342 , May 2010